Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Capital Expenditures (2016 - 2025)

Ani Pharmaceuticals' Capital Expenditures history spans 16 years, with the latest figure at -$11.5 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 10787.74% year-over-year to -$11.5 million; the TTM value through Dec 2025 reached $1.0 million, up 98.49%, while the annual FY2025 figure was $1.0 million, 98.49% up from the prior year.
  • Capital Expenditures for Q4 2025 was -$11.5 million at Ani Pharmaceuticals, down from $12.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $12.3 million in Q3 2025 and bottomed at -$11.5 million in Q4 2025.
  • The 5-year median for Capital Expenditures is $1.4 million (2021), against an average of $973750.0.
  • The largest annual shift saw Capital Expenditures skyrocketed 2430.65% in 2022 before it plummeted 10787.74% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $124000.0 in 2021, then surged by 2430.65% to $3.1 million in 2022, then dropped by 27.37% to $2.3 million in 2023, then plummeted by 104.65% to -$106000.0 in 2024, then tumbled by 10787.74% to -$11.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Capital Expenditures are -$11.5 million (Q4 2025), $12.3 million (Q3 2025), and -$2.2 million (Q2 2025).